European Archives of Psychiatry and Clinical Neuroscience
December 2011
Laura Kranaster, Jutta Kammerer-Ciernioch, Carolin Hoyer et al.
In a retrospective chart review, we examined the effects of ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, as electroconvulsive therapy (ECT) anaesthetic in patients suffering from therapy-resistant depression. We included 42 patients who received ECT treatment with either ketamine (n = 16) or the barbiturate thiopental (n = 26). We analysed the number of sessions until...
Neuropsychopharmacology
December 2011
Samantha L Rushforth, Thomas Steckler, Mohammed Shoaib
Ketamine, an NMDA-receptor antagonist, produces cognitive deficits in humans in a battery of tasks involving attention and memory. Nicotine can enhance various indices of cognitive performance, including working memory span capacity measured using the odor span task (OST). This study examined the effects of a sub-chronic ketamine treatment to model cognitive deficits associated with...
Toxicology Letters
November 30, 2011
W M Chan, Y Liang, Maria S M Wai et al.
Increased use of ketamine as a recreational drug in rave party has raised lots of social concerns. Although its toxicity on the central nervous system (CNS) and urinary system had been reported, its potential adverse effects on the heart is still not addressed. Using our long term ketamine addiction model in which, 1-month-old ICR mice were given ketamine intraperitoneally (i.p. 30 mg/kg) for...
The International Journal of Neuropsychopharmacology
November 1, 2011
Giacomo Salvadore, Jan Willem van der Veen, Yan Zhang et al.
105 citations
Amino-acid neurotransmitter system dysfunction plays a major role in the pathophysiology of major depressive disorder (MDD). We used proton magnetic resonance spectroscopy (¹H-MRS) to investigate whether prefrontal levels of amino-acid neurotransmitters predict antidepressant response to a single intravenous infusion of the N-methyl-D-aspartate (NMDA) antagonist ketamine in MDD patients....
Journal of Clinical Psychopharmacology
October 21, 2011
Erica Neill, Susan Lee Rossell, Sarah McDonald et al.
11 citations
Semantic deficits constitute a core cognitive abnormality in schizophrenia. In the current study, the N-methyl-d-aspartate receptor antagonist ketamine was administered to healthy individuals acutely while they performed semantic processing tasks that included word pairs of differing degrees of semantic relatedness. Two dimensions of semantic processing were investigated: (1) explicit versus...
Anesthesiology
October 1, 2011
Jing Wang, Yossef Goffer, Duo Xu et al.
171 citations
BACKGROUND: Chronic pain is associated with depression. In rodents, pain is often assessed by sensory hypersensitivity, which does not sufficiently measure affective responses. Low-dose ketamine has been used to treat both pain and depression, but it is not clear whether ketamine can relieve depression associated with chronic pain and whether this antidepressant effect depends on its...
Psychopharmacology
September 15, 2011
Agnieszka Nikiforuk, Piotr Popik
Rationale: Prefrontal cortical dysfunctions, including an impaired ability to shift perceptual attentional set, are core features of schizophrenia. Nevertheless, the effectiveness of second-generation antipsychotic drugs in treating specific prefrontal dysfunctions remains equivocal. Objectives: To model schizophrenia-like cognitive inflexibility in rats, we evaluated the effects of repeated...
Pharmacopsychiatry
September 1, 2011
Patrik Roser, IS Haussleiter, HJ Chong et al.
2 citations
Preclinical and clinical research suggests that the endogenous cannabinoid system is involved in cognitive impairments related to schizophrenia. In particular, deficient generation of mismatch negativity (MMN) indicating auditory sensory memory is a characteristic finding in schizophrenic patients. Experimental studies implicate deficient N-methyl-D-aspartate (NMDA) receptor functioning in such...
International Clinical Psychopharmacology
September 1, 2011
Silvia Sorce, Stefania Schiavone, Paolo Tucci et al.
The 15th Biennial Winter Workshop in Psychoses, 15–18 November 2009, Barcelona, Spain: DRUG INDUCED PSYCHOSES
International Clinical Psychopharmacology
September 1, 2011
Hannah L. Morgan, J.C. Coull, J.G. Moore et al.
The 16th Biennial Winter Workshop in Psychoses, 30 January to 2 February 2011 Innsbruck, Austria: POSTER ABSTRACTS